Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

Coenzyme Q10 (CoQ10) and creatine are promising agents for neuroprotection in neurodegenerative diseases via their effects on improving mitochondrial function and cellular bioenergetics and their properties as antioxidants. We examined whether a combination of CoQ10 with creatine can exert additive neuroprotective effects in a MPTP mouse model of Parkinson’s disease, a 3‐NP rat model of Huntington’s disease (HD) and the R6/2 transgenic mouse model of HD. The combination of the two agents produced additive neuroprotective effects against dopamine depletion in the striatum and loss of tyrosine hydroxylase neurons in the substantia nigra pars compacta (SNpc) following chronic subcutaneous administration of MPTP. The combination treatment resulted in significant reduction in lipid peroxidation and pathologic α‐synuclein accumulation in the SNpc neurons of the MPTP‐treated mice. We also observed additive neuroprotective effects in reducing striatal lesion volumes produced by chronic subcutaneous administration of 3‐NP to rats. The combination treatment showed significant effects on blocking 3‐NP‐induced impairment of glutathione homeostasis and reducing lipid peroxidation and DNA oxidative damage in the striatum. Lastly, the combination of CoQ10 and creatine produced additive neuroprotective effects on improving motor performance and extending survival in the transgenic R6/2 HD mice. These findings suggest that combination therapy using CoQ10 and creatine may be useful in the treatment of neurodegenerative diseases such as Parkinson’s disease and HD.

[1]  A. Othman,et al.  Experimental schistosomal hepatitis: protective effect of coenzyme-Q10 against the state of oxidative stress. , 2008, Experimental parasitology.

[2]  C. Schade-Brittinger,et al.  Short‐term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo‐controlled trial , 2008, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Sawangkoon,et al.  Protective effect of creatine supplementation and estrogen replacement on cardiac reserve function and antioxidant reservation against oxidative stress in exercise-trained ovariectomized hamsters. , 2008, International heart journal.

[4]  M. Beal,et al.  Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism , 2008, Journal of neurochemistry.

[5]  Geng Li,et al.  Coenzyme Q10 Attenuates β-Amyloid Pathology in the Aged Transgenic Mice with Alzheimer Presenilin 1 Mutation , 2008, Journal of Molecular Neuroscience.

[6]  A. Kupsch,et al.  Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. , 2007, Archives of neurology.

[7]  M. Bloom.  NIH announces phase III clinical trial of creatine for Parkinson's disease. , 2007, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[8]  U. Lindauer,et al.  Improved Reperfusion and Neuroprotection by Creatine in a Mouse Model of Stroke , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  Oliver Holub,et al.  Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation , 2006, Journal of Biological Chemistry.

[10]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[11]  Wayne R Matson,et al.  Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. , 2006, Biochimica et biophysica acta.

[12]  R. Homayouni,et al.  The Creatine Kinase/Creatine Connection to Alzheimer's Disease: CK Inactivation, APP-CK Complexes, and Focal Creatine Deposits , 2006, Journal of biomedicine & biotechnology.

[13]  Ninds Net-Pd Investigators.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[14]  R. Elble,et al.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease , 2006, Neurology.

[15]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[16]  A. Pestronk,et al.  Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS , 2005, Neurology.

[17]  A. Contestabile,et al.  Neurochemical correlates of differential neuroprotection by long-term dietary creatine supplementation , 2005, Brain Research.

[18]  Y. Moon,et al.  Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10 , 2005, Journal of neurochemistry.

[19]  A. Blamire,et al.  Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. , 2005, Archives of neurology.

[20]  M. Sikorska,et al.  Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10 , 2005, Neurobiology of Disease.

[21]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Beal,et al.  A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities , 2005, Experimental Neurology.

[23]  S McCarthy,et al.  Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. , 2004, Toxicology and applied pharmacology.

[24]  Steven M. Hersch,et al.  Translating therapies for Huntington’s disease from genetic animal models to clinical trials , 2004, NeuroRX.

[25]  Robert H. Brown,et al.  Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice , 2004, The Journal of Neuroscience.

[26]  M. Beal,et al.  Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.

[27]  M. Beal,et al.  Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase , 2004, Neurobiology of Disease.

[28]  G. Dallner,et al.  Metabolism and function of coenzyme Q. , 2004, Biochimica et biophysica acta.

[29]  M. Beal,et al.  Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis , 2003, Journal of neurochemistry.

[30]  S. Swinnen,et al.  Creatine supplementation in Huntington’s disease , 2003, Neurology.

[31]  Ewa Witort,et al.  Coenzyme Q10 Prevents Apoptosis by Inhibiting Mitochondrial Depolarization Independently of Its Free Radical Scavenging Property* , 2003, Journal of Biological Chemistry.

[32]  T. Wallimann,et al.  Inhibition of the Mitochondrial Permeability Transition by Creatine Kinase Substrates , 2003, The Journal of Biological Chemistry.

[33]  Wenhua Zhang,et al.  Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS , 2003, Annals of neurology.

[34]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[35]  K. Fouad,et al.  Protective effects of oral creatine supplementation on spinal cord injury in rats , 2002, Spinal Cord.

[36]  Shawn D. Chase,et al.  Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[38]  J. Stuart,et al.  Superoxide activates mitochondrial uncoupling proteins , 2002, Nature.

[39]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[40]  M. Beal,et al.  Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders , 2001, Annals of neurology.

[41]  J. Dubinsky,et al.  On the mechanisms of neuroprotection by creatine and phosphocreatine , 2001, Journal of neurochemistry.

[42]  M. Mattson,et al.  Dietary supplement creatine protects against traumatic brain injury , 2000, Annals of neurology.

[43]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[44]  G J Brewer,et al.  Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β‐Amyloid in Rat Hippocampal Neurons , 2000, Journal of neurochemistry.

[45]  F. Condé,et al.  Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies , 2000, Neuroscience.

[46]  M. Beal,et al.  Neuroprotective effects of creatine administration against NMDA and malonate toxicity , 2000, Brain Research.

[47]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[48]  O. Andreassen,et al.  Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.

[49]  K. Ikeda,et al.  Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[50]  R. Stocker,et al.  Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. , 1999, Free radical biology & medicine.

[51]  I. Pogribny,et al.  A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. , 1999, The Journal of nutritional biochemistry.

[52]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[53]  S. Browne,et al.  Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Beal,et al.  Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.

[55]  Bruce R. Rosen,et al.  Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.

[56]  G. Dallner,et al.  Biochemical, physiological and medical aspects of ubiquinone function. , 1995, Biochimica et biophysica acta.

[57]  B. Rosen,et al.  Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate , 1994, Annals of neurology.

[58]  W. Augustin,et al.  Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. , 1994, Free radical research.

[59]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  L. Packer,et al.  Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. , 1990, Biochemical and biophysical research communications.

[61]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[62]  M. Beal,et al.  Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[63]  M. Beal,et al.  Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease , 2007, Journal of Molecular Neuroscience.

[64]  T. Hofer,et al.  A method to determine RNA and DNA oxidation simultaneously by HPLC-ECD: greater RNA than DNA oxidation in rat liver after doxorubicin administration , 2006, Biological chemistry.

[65]  C. Shults,et al.  Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease , 2003, BioFactors.

[66]  O. Andreassen,et al.  Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. , 2001, Neurobiology of disease.

[67]  P. Forsmark-Andrée,et al.  Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. , 1997, Free radical biology & medicine.